← Back to home

Hormone receptor+/human epidermal growth factor receptor 2 negative breast cancer

Clinical trials for Hormone receptor+/human epidermal growth factor receptor 2 negative breast cancer explained in plain language.

Never miss a new study

Get alerted when new Hormone receptor+/human epidermal growth factor receptor 2 negative breast cancer trials appear

Sign up with your email to follow new studies for Hormone receptor+/human epidermal growth factor receptor 2 negative breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New cancer drug ABBV-400 enters early human testing

Disease control Recruiting now

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

Matched conditions: HORMONE RECEPTOR+/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER

Phase 1 • Sponsor: AbbVie • Aim: Disease control

Last updated Aug 26, 2026 00:00 UTC

Hormone receptor+/human epidermal growth factor receptor 2 negative breast cancer

Get alerted when new Hormone receptor+/human epidermal growth factor receptor 2 negative breast cancer trials appear

New cancer drug ABBV-400 enters early human testing